Literature DB >> 19504230

Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis.

Jorge Rojas-Serrano1, Rubén Burgos-Vargas, Leticia Lino Pérez, Conrado García García, Francisco Moctezuma, Janitzia Vázquez-Mellado.   

Abstract

The objective of this study is to identify baseline factors associated with rheumatoid arthritis (RA) diagnosis at the end of 1-year follow-up in a cohort of patients with very recent onset arthritis. Incident cases with self-reported arthritis (<or=12 weeks) referred by primary care physicians were assessed by a designated rheumatologist who predicted in those with >or=1 swollen joint the diagnosis of RA at the end of follow-up. Patients were regularly seen and diagnosed through follow-up by staff rheumatologists who were blind to diagnostic prediction. Of 119 referrals, 78 (65.5%; age 35.5 +/- 13.5 years; 69 females) were diagnosed at baseline as very recent onset arthritis (median duration 6 weeks (0-12 weeks)); of 75 patients completing 1-year follow-up, 51 (66.5%) were classified as RA; 12 (16%) had self-limited arthritis; and 13 (17.5%) other diagnoses. The characteristics of patients with RA as final diagnosis were polyarthritis, morning stiffness >or=1 h, high counts of swollen joints, and low frequency of systemic symptoms. Rheumatologist prediction of RA and anti-cyclic citrullinated peptide (anti-CCP) antibodies was strongly associated with RA as a final diagnosis in the logistic regression analysis. Sensitivity and specificity of the rheumatologist prediction were 94% and 74%, for anti-CCP antibodies, 56% and 96%; the combination of both variables had a specificity of 100% and a sensitivity of 53%, and a positive predictive value of 98%. The combination of RA as predicted diagnosis by a rheumatologist and anti-CCP antibodies is highly specific for RA diagnosis in patients with very early arthritis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19504230     DOI: 10.1007/s10067-009-1206-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  16 in total

Review 1.  Therapeutic strategies for rheumatoid arthritis.

Authors:  James R O'Dell
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

2.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

Authors:  G A Schellekens; H Visser; B A de Jong; F H van den Hoogen; J M Hazes; F C Breedveld; W J van Venrooij
Journal:  Arthritis Rheum       Date:  2000-01

3.  How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis.

Authors:  Henk Visser; Saskia le Cessie; Koen Vos; Ferdinand C Breedveld; Johanna M W Hazes
Journal:  Arthritis Rheum       Date:  2002-02

4.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

5.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

Authors:  Hyon K Choi; Miguel A Hernán; John D Seeger; James M Robins; Frederick Wolfe
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

6.  A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions.

Authors:  Annette H M van der Helm-van Mil; Saskia le Cessie; Henrike van Dongen; Ferdinand C Breedveld; René E M Toes; Tom W J Huizinga
Journal:  Arthritis Rheum       Date:  2007-02

Review 7.  Natural remission in inflammatory polyarthritis: issues of definition and prediction.

Authors:  B J Harrison; D P Symmons; P Brennan; E M Barrett; A J Silman
Journal:  Br J Rheumatol       Date:  1996-11

8.  Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study.

Authors:  C Egsmose; B Lund; G Borg; H Pettersson; E Berg; U Brodin; L Trang
Journal:  J Rheumatol       Date:  1995-12       Impact factor: 4.666

9.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.

Authors:  Markus M J Nielen; Dirkjan van Schaardenburg; Henk W Reesink; Rob J van de Stadt; Irene E van der Horst-Bruinsma; Margret H M T de Koning; Moud R Habibuw; Jan P Vandenbroucke; Ben A C Dijkmans
Journal:  Arthritis Rheum       Date:  2004-02

10.  Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease-modifying drugs.

Authors:  M Abu-Shakra; R Toker; D Flusser; G Flusser; M Friger; S Sukenik; D Buskila
Journal:  Arthritis Rheum       Date:  1998-07
View more
  4 in total

1.  Diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody for rheumatoid arthritis.

Authors:  Behzad Heidari; Hassan Abedi; Alireza Firouzjahi; Parnaz Heidari
Journal:  Rheumatol Int       Date:  2009-10-13       Impact factor: 2.631

2.  Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis.

Authors:  Kumi Shidara; Eisuke Inoue; Eiichi Tanaka; Daisuke Hoshi; Yohei Seto; Ayako Nakajima; Shigeki Momohara; Atsuo Taniguchi; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-01-05       Impact factor: 2.631

3.  A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis.

Authors:  Peter Taylor; Juliane Gartemann; Jeanie Hsieh; James Creeden
Journal:  Autoimmune Dis       Date:  2011-09-11

4.  Anti-cyclic citrullinated peptide antibodies and joint involvement in Behçet's disease.

Authors:  Sung Bin Cho; Ju Hee Lee; Keun Jae Ahn; Byung Gi Bae; Taegyun Kim; Yong-Beom Park; Soo-Kon Lee; Kwang Hoon Lee; Dongsik Bang
Journal:  Yonsei Med J       Date:  2012-07-01       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.